Metformin Effects on FOXP3
Publication/Presentation Date
9-1-2020
Abstract
OBJECTIVES: Alterations of cellular metabolism have been implicated in immune dysfunction in the tumor microenvironment (TME) of head and neck squamous cell carcinoma (HNSCC). Metformin has recently emerged as a candidate of interest for combination with immunotherapy in HNSCC. This study investigated the effect of metformin on immune cell infiltrates of HNSCC.
METHODS: Retrospective analysis of T cell infiltrates in primary tumor specimens from patients enrolled in a clinical window of opportunity trial of presurgical metformin. Metformin was titrated to a standard diabetic dose (2000 mg/day) for a minimum of 9 days (mean 13.6 days) prior to surgical resection. Pre and posttreatment surgical specimens from 36 patients (16 HPV
RESULTS: Metformin treatment was associated with a 41.4% decrease in FOXP3
CONCLUSION: Metformin treatment may favorably alter the immune TME in HNSCC independent of HPV status.
LEVEL OF EVIDENCE: 1b. This study is most accurately described as a non-randomized controlled trial and therefore may reflect a level of evidence below 1b but above 2a from the provided "levels of evidence" chart. Laryngoscope, 130:E490-E498, 2020.
Volume
130
Issue
9
First Page
490
Last Page
490
ISSN
1531-4995
Published In/Presented At
Amin, D., Richa, T., Mollaee, M., Zhan, T., Tassone, P., Johnson, J., Luginbuhl, A., Cognetti, D., Martinez-Outschoorn, U., Stapp, R., Solomides, C., Rodeck, U., & Curry, J. (2020). Metformin Effects on FOXP3+ and CD8+ T Cell Infiltrates of Head and Neck Squamous Cell Carcinoma. The Laryngoscope, 130(9), E490–E498. https://doi.org/10.1002/lary.28336
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
31593308
Department(s)
Administration and Leadership
Document Type
Article